India Biotechnology Market Trends 2025: Size, Share, Growth Rate & Industry Outlook 2033
According to the latest report by IMARC Group, titled "India Biotechnology Market Report by Product Type (Instruments, Reagents, Software and Services), Technology (Nanobiotechnology, Tissue Engineering and Regeneration, DNA Sequencing, Cell-Based Assays, Fermentation, PCR Technology, Chromatography, and Others), Application (Healthcare, Food and Agriculture, Natural Resources and Environment, Industrial Processing, Bioinformatics, and Others), and Region 2024-2032," the report presents a thorough review featuring the India Biotechnology Market trends, growth, share, and research of the industry.
Market Size & Future Growth Potential:
The India biotechnology market size reached USD 32.6 Billion in 2024 and expects the market to reach USD 110.3 Billion by 2033, exhibiting a growth rate (CAGR) of 13.78% during 2025-2033.
Latest Market Trends:
India's biotechnology sector is experiencing a transformative phase driven by multiple dynamic forces. The sector is witnessing exponential startup growth, expanding from approximately 50 startups in 2014 to nearly 9,000 by the end of 2024, with projections to reach 10,000 by 2025. This remarkable entrepreneurial momentum reflects the maturation of India's bio-innovation ecosystem.
The biopharmaceutical segment continues to dominate the landscape, accounting for 58% of the industry and contributing approximately 49% to India's bioeconomy with an economic value of USD 39.4 billion. The vaccination market alone is projected to reach Rs. 252 billion (USD 3.04 billion) by 2025, highlighting the sector's critical role in public health infrastructure. India maintains its position as the world's largest vaccine manufacturer by volume, accounting for 60% of global vaccine production and contributing 40-70% of WHO demand for essential vaccines including Diphtheria, Tetanus and Pertusus (DPT).
The biosimilars segment is experiencing robust expansion, with India hosting the highest number of approved biosimilars in its domestic market and maintaining leadership in affordable biologics globally. Major Indian companies are making strategic inroads into developed markets, with notable launches in the United States market demonstrating the maturation of India's biologics capabilities.
Agricultural biotechnology is advancing rapidly through innovations in genomics and gene editing, with the government's Agriculture Biotechnology programme developing climate-smart crop varieties. A drought-tolerant, high-yielding chickpea variety (SAATVIK NC 9) has been approved for cultivation, exemplifying the sector's contribution to food security. The bio-agriculture segment holds potential to nearly double its contribution from USD 10.5 billion to USD 20 billion by 2025.
India's bioeconomy has grown sixteen-fold from USD 10 billion in 2014 to USD 165.7 billion in 2024, representing approximately 4.25% of the country's GDP and employing over 2 million people. The Department of Biotechnology's budget has increased by nearly 130%, rising from Rs. 1,485 crore in 2013-14 to Rs. 3,447 crore in 2025-26, reflecting sustained governmental commitment to the sector.
Request Free Sample Report: https://www.imarcgroup.com/india-biotechnology-market/requestsample
Market Scope and Growth Factors:
The India biotechnology market scope is expanding significantly, driven by the country's vast skilled workforce, world-class infrastructure, and robust government support mechanisms. India operates the largest number of US FDA-approved pharmaceutical plants outside the United States, with over 665 facilities, positioning it as a critical global biomanufacturing hub.
Strategic government initiatives are providing unprecedented momentum to the sector. The National Biotechnology Development Strategy (NBDS) 2021-2025 aims to establish India as a USD 150 billion bioeconomy by 2025, focusing on making India globally competitive in biotechnology research, innovation, and industrial growth. The BioE3 (Biotechnology for Economy, Environment and Employment) Policy approved by the Union Cabinet in 2024 envisions creating a USD 300 billion bioeconomy by 2030 through fostering high-performance biomanufacturing.
The Production-Linked Incentive (PLI) scheme, along with the establishment of bulk drug parks, is bolstering domestic manufacturing capabilities and reducing import dependence. The Bio-RIDE (Biotechnology Research Innovation and Entrepreneurship Development) scheme, with an allocated budget of Rs. 9,197 crore for 2021-22 to 2025-26, consolidates research and development efforts while introducing a new biomanufacturing and biofoundry component.
The Biotechnology Industry Research Assistance Council (BIRAC) has established 95 bio-incubation centers nationwide, providing critical infrastructure, funding, and mentorship to startups. As of October 2024, the Department of Biotechnology oversees 1,547 ongoing projects, demonstrating the breadth of research and development activities across the ecosystem.
India's favorable FDI policy allows 100% Foreign Direct Investment under the automatic route for greenfield pharmaceutical projects and medical device manufacturing, attracting substantial international investment. Strategic global collaborations between Indian firms and international pharmaceutical giants are accelerating technology transfer and capacity building. The country is emerging as a preferred destination for contract research and manufacturing services (CRAMS), ranking as the second-largest Contract Development and Manufacturing Organization (CDMO) player globally for small molecules.
The integration of advanced technologies including artificial intelligence, machine learning, and advanced analytics into biotechnology is driving innovation in precision medicine, drug discovery, and clinical trials. The bioinformatics market, supported by India's robust IT infrastructure and skilled workforce, is projected to witness significant growth through initiatives like the Biotechnology Information System Network.
The increasing prevalence of chronic diseases including cancer, diabetes, and cardiovascular disorders has created substantial demand for innovative biotechnological solutions for diagnosis, treatment, and prevention. The convergence of information technology with biotechnology is fostering data-driven insights and personalized medicine approaches, addressing the growing demand for targeted therapeutic solutions.
Comprehensive Market Report Highlights & Segmentation Analysis:
The market report offers a comprehensive analysis of the segments, highlighting those with the largest India biotechnology market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.
Segmentation by Product Type:
Instruments
Reagents
Software and Services
Segmentation by Technology:
Nanobiotechnology
Tissue Engineering and Regeneration
DNA Sequencing
Cell-Based Assays
Fermentation
PCR Technology
Chromatography
Others
Segmentation by Application:
Healthcare
Food and Agriculture
Natural Resources and Environment
Industrial Processing
Bioinformatics
Others
Segmentation by Region:
North India
West and Central India
South India
East and Northeast India
Competitor Landscape:
The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant. The companies in the market are adopting various strategic initiatives including new product launches and business alliances to gain a significant India biotechnology market share.
Recent News and Developments:
Union Budget 2025-26 Strengthens Biotech Funding: The budget allocated Rs. 20,000 crore (USD 2.30 billion) for private research, launched the National Manufacturing Mission, and promoted AI-driven biotechnology, precision farming, biofuels, and genetic research, driving innovation and sustainability across the sector.
National Speed Breeding Crop Facility Inaugurated: In March 2024, Union Minister Dr. Jitendra Singh inaugurated the pioneering "National Speed Breeding Crop Facility" at the National Agri-Food Biotechnology Institute (NABI) in Mohali, accelerating crop improvement research and development.
Biotech Startups Expo in North India: In January 2024, the Biotech Startups Expo on "Emerging Startup Trends in North India" was inaugurated at Biotech Park, Kathua, showcasing innovation and entrepreneurship in the region.
India's First Indigenous HPV Vaccine: India developed the world's first indigenously developed quadrivalent Human Papilloma Virus (qHPV) vaccine against cervical cancer, supported by DBT and BIRAC, which received market authorization from DCGI in July 2022.
Reliance Life Sciences Receives USFDA Approval: In December 2023, Reliance Life Sciences received USFDA approval for a generic Insulin Glargine injection, marking significant development for India's biosimilars industry and potentially increasing access to critical diabetes medication.
Bharat Biotech's Chikungunya Vaccine Success: In November 2023, Bharat Biotech announced successful Phase 3 trials for its indigenously developed chikungunya vaccine, offering hope for preventing this mosquito-borne viral infection prevalent in India.
Strategic Biocon-Merck Partnership: In October 2023, Biocon signed a strategic partnership with Merck for biosimilar development, signifying international recognition for Indian biotechnology capabilities and strengthening global collaboration.
Serum Institute-Biocon Strategic Alliance: Serum Institute Life Sciences doubled its investment in Biocon Biologics to USD 300 million, providing Biocon access to 100 million doses of vaccines annually and distribution rights to Serum's vaccine portfolio for global markets.
Bharat Biotech Expands Cell and Gene Therapy: Bharat Biotech invested USD 75 million into building cell and gene therapy capacity, positioning India to participate in next-generation therapeutic modalities.
Bioenergy Milestone Achieved: India's ethanol blending in fuel increased significantly from 1.53% in 2014 to 15% in 2024, with a target of 20% blending by 2025, demonstrating progress in sustainable biofuel adoption.
Explore the Full Report with Charts, Table of Contents, and List of Figures: https://www.imarcgroup.com/india-biotechnology-market
Key highlights of the Report:
Historical Market Performance
Future Market Projections
Impact of COVID-19 on Market Dynamics
Industry Competitive Analysis (Porter's Five Forces)
Market Dynamics and Growth Drivers
SWOT Analysis (Strengths, Weaknesses, Opportunities, Threats)
Market Ecosystem and Value Creation Framework
Competitive Positioning and Benchmarking Strategies
Major Advantages of the Report:
This report provides market leaders and new entrants with accurate revenue estimates for the overall market and its key subsegments.
Stakeholders can leverage this report to gain a deeper understanding of the competitive landscape, enabling them to strategically position their businesses and develop effective go-to-market strategies.
The report provides stakeholders with valuable insights into the market dynamics, offering a comprehensive analysis of key drivers, restraints, challenges, and opportunities.
Why Choose IMARC Group:
Extensive Industry Expertise
Robust Research Methodology
Insightful Data-Driven Analysis
Precise Forecasting Capabilities
Established Track Record of Success
Reach with an Extensive Network
Tailored Solutions to Meet Client Needs
Commitment to Strong Client Relationships and Focus
Timely Project Delivery
Cost-Effective Service Options
Note: Should you require specific information not included in the current report, we are pleased to offer customization options to meet your needs.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
Contact US
IMARC Group 134 N 4th St. Brooklyn, NY 11249, USA Email: Sales@imarcgroup.com Tel No:(D) +91 120 433 0800 Americas: +1-201971-6302 | Africa and Europe: +44-702-409-7331
Last updated